Journal

Supplier nationality, CE conformity, hosting and clinical quality are different questions. A practical framework for comparing European, British and American medical AI.

The strategic bottleneck in healthcare AI may be access to clinical work rather than the underlying model. Examine distribution, switching costs, open interfaces and procurement ch...

Three scenarios for clinical AI competition after indefinite CE recognition: broader choice, stronger integrated platforms or slower adoption despite easier market access.

A shared clinical AI interface can contain functions with different purposes and risks. Tandem's expanding suite shows why product boundaries and change control matter.

Tandem's integrations reveal a competition over clinical distribution. Connection depth, maintenance, partner dependence and exit arrangements matter more than logo counts.

Tandem's ambition extends beyond documentation. What it would take to coordinate clinical work reliably, and where specialist tools could remain important.

From local safety cases to integration and review burden, the practical work that separates a recognised medical device from a dependable NHS deployment.

A timeline of CE recognition, UKCA and AI reform, explaining why market access, domestic oversight and industrial competitiveness are evolving separately.

Reduced regulatory duplication does not guarantee lower NHS prices. How to analyse competition, implementation costs and the value of time saved by clinical AI.

How to compare intended purpose, classification, evidence, market access and lifecycle costs after the UK decision on indefinite CE recognition.

Indefinite CE recognition reduces duplication but raises a harder question: where should Britain exercise independent judgement over clinical AI?

European clinical AI gains market-access certainty, but the policy also benefits qualifying British and global suppliers. Who can turn recognition into adoption?